持续静脉泵注恩度联合SOX方案治疗原发性肝癌  

Clinical efficacy of combination therapy with continuous intravenous pumping of Endostar and SOX regimen in advanced primary carcinoma of the liver

作　　者：苏进[1] 许新华[1] 史克志 易芳[1] 刘洋[1] 

机构地区：[1]三峡大学第一临床医学院&宜昌市中心人民医院肿瘤科,湖北省宜昌市443003 [2]三峡大学肿瘤防治中心,湖北省宜昌市443002

出　　处：《实用医学杂志》2016年第17期2908-2911,共4页The Journal of Practical Medicine

基　　金：中华国际医学交流会基金会项目(编号:CIMF-FH001-312)

摘　　要：目的：观察重组人血管内皮抑制素（恩度）持续泵注联合SOX方案化疗对中晚期原发性肝癌的有效性及安全性。方法：将2012年2月至2014年8月我院收治的32例中晚期原发性肝癌患者接受持续静脉泵注恩度联合SOX方案治疗：奥沙利铂注射液130mg／m2，dl；替吉奥胶囊80～120mg／（m2．d）．dl～14；恩度150mg＋生理盐水210mL，便携式微量泵2mL／h连续泵注120h；每21天为1周期：每2个周期评价客观疗效及不良反应；并动态检测血清甲胎蛋白水平的变化。结果：32例患者均可评价疗效．客观有效率、疾病控制率、临床收益率、1年生存率分别为15．6％、46．9％、56．3％和58．3％；血清甲胎蛋白（AFP）反应率为19．4％。常见的不良反应主要为骨髓抑制和疲乏，主要为Ⅰ～Ⅱ级，无化疗相关性死亡。结论：持续静脉泵注恩度联合SOX方案治疗中晚期原发性肝癌具有较好的生存质量和生存获益．不良反应可耐受。Objective To evaluate the efficacy and safety of combination therapy of Endostar and oxaliplatin plus S-1 （ SOX regimen） in patients with advanced Primary carcinoma of the liver. Methods 32 advanced primary liver cancer patients admitted from February 2012 to August 2014 were assigned to SOX regimen as systemic chemotherapy： oxaliplatin 130 mg/m2 iv dl; S-1 （80 - 120 mg, twice-daily） for 14 days; 150 mg Endostar which was dissolved in 210 mL normal saline for 120 h durative transfusion. Treatment was repeated every 21 days. Objective clinical efficacy and adverse effect was assessed every 2 cycles. Serum alpha fetoprotein （AFP） level was also monitored according to the schedule. Results All 32 patients were available to be assessed, the objective response rate （ORR）, disease control rate （DCR） ,the clinical benefit response rates （CBR）, 1 year survival rate was 15.6%, 46.9%, 56.3%, 58.3% respectively. The serum AFP respond rate was 19.4%. Major adverse effects were myelosuppression and fatigue, mostly graded at 1 - 2. There were no treatment- related death. Conclusions These preliminary results suggest that continuous intravenous pumping of Endostar combined with SOX regimen could provide survival benefits with tolerable adverse effects.

关 键 词：原发性肝癌 替吉奥胶囊 奥沙利铂 重组人血管内抑制素 

分 类 号：R735.7[医药卫生—肿瘤]